| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Jack Nielsen last filed a Form 4 in May 2024, as Director at TIL. The filings on record cover 3 companies. Jack Nielsen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Jack Nielsen a strong insider score of 76/100, based on 53 past trades. Over a 12-month horizon, 96.2% of those trades were profitable, with an average 12-month return of +33.4%.
At the last filing, the largest reported position was 2,571,024 shares of HRMY. The HRMY filings lean toward selling, a net 1,729,242 shares.
Jack Nielsen has 45 Form 4 filings on record from June 2019 to May 2024, across 6 companies: Director at Harmony Biosciences (HRMY), 2020–2024; Director at Aligos Therapeutics (ALGS), 2021–2024; Director, 10% Owner at Alx Oncology (ALXO), 2020–2023, and 3 more.
The 99 reported transactions were 68 open-market sales, 19 option or other derivative awards, 8 open-market purchases and 3 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 4 purchases worth about $16.3M and 22 sales worth about $96.5M.
The largest open-market purchase was 650,000 shares of IOBT at an average $14.00 on November 9, 2021, about $9.1M. Twelve months later IOBT was down 81%.
The largest open-market sale was 300,741 shares of HRMY at an average $55.39 on July 7, 2022, about $16.7M. Twelve months later HRMY was down 40%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 14, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 2,834 | $59.96 | $169,926.64 | -0.1% | -29.2% | -42.4% | |
| Dec 9, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 110,751 | $60.16 | $6,662,698.13 | -4.1% | -27.6% | -47.5% | |
| Dec 1, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 129,652 | $59.29 | $7,686,960.37 | -4.6% | -28.6% | -49.2% | |
| Nov 22, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 77,600 | $57.27 | $4,444,333.04 | -2.7% | -24.4% | -50.8% | |
| Nov 15, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 158,400 | $57.58 | $9,121,099.30 | -5.2% | -16.3% | -55.1% | |
| Aug 8, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 250,000 | $52.73 | $13,183,300.00 | -7.6% | +5.8% | -38.3% | |
| Aug 2, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 75,117 | $55.22 | $4,147,960.74 | -2.2% | -6.2% | -41.2% | |
| Jul 18, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 40,087 | $55.19 | $2,212,401.53 | -1.2% | -5.8% | -30.6% | |
| Jul 13, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 5,773 | $55.04 | $317,745.92 | -0.2% | -11.6% | -35.8% | |
| Jul 11, 2022 | HRMY Harmony Biosciences Holdings, Inc. | Director | Sell | 10,768 | $55.05 | $592,810.28 | -0.3% | -13.5% | -37.4% |